Proton Pump Inhibitor References

• Abramowitz J, Thakkar P, Isa A, Truong A, Park C, Rosenfeld RM. Adverse Event Reporting for Proton Pump Inhibitor Therapy: An Overview of Systematic Reviews. Otolaryngol Head Neck Surg. 2016;155(4):547-554.

• Benmassaoud A, McDonald EG, Lee TC. Potential harms of proton pump inhibitor therapy: rare adverse effects of commonly used drugs. CMAJ. 2015.

• Canadian Association of Gastroenterology recommendation, 2017. Available: www.choosingwiselycanada.org/gastroenterology

• Farrell B, Pottie K, Thompson W, Boghossian T, Pizzola L, Rashid FJ, Rojas-Fernandez C, Walsh K, Welch V, Moayyedi P. Deprescribing proton pump inhibitors: Evidence-based clinical practice guideline. Can Fam Physician. 2017;63(5):354-364.   

• Juul-Hansen, P. and Rydning, A. (2011). Clinical and pathophysiological consequences of on-demand treatment with PPI in endoscopy-negative reflux disease. Is rebound hypersecretion of acid a problem? Scand J Gastroenterol 46(4): 398-405. 

• Niklasson, A., Lindstrom, L., Simren, M., et al. (2010). Dyspeptic symptom development after discontinuation of a proton pump inhibitor: a double-blind placebo-controlled trial. Am J Gastroenterol 105(7): 1531-1537.

• Reimer, C., Sondergaard, B., Hilsted, L., et al. (2009). Proton-pump inhibitor therapy induces acid-related symptoms in healthy volunteers after withdrawal of therapy. Gastroenterology 137(1): 80-87, 87 e81.

• Schoenfeld AJ, Grady D. Adverse Effects Associated With Proton Pump Inhibitors. JAMA Intern Med. 2016:1-3.

Sedative References

• Alessi, C., Martin, J. L., Fiorentino, L., et al. (2016). "Cognitive Behavioral Therapy for Insomnia in Older Veterans Using Nonclinician Sleep Coaches: Randomized Controlled Trial." J Am Geriatr Soc 64(9): 1830-1838

• Bakken, M. S., Engeland, A., Engesaeter, L. B., et al. (2014). "Risk of hip fracture among older people using anxiolytic and hypnotic drugs: a nationwide prospective cohort study." Eur J Clin Pharmacol 70(7): 873-880.

• Billioti de Gage, S., Begaud, B., Bazin, F., et al. (2012). "Benzodiazepine use and risk of dementia: prospective population based study." BMJ 345: e6231.

• Buscemi, N., Vandermeer, B., Pandya, R., et al. (2004). "Melatonin for treatment of sleep disorders." Evid Rep Technol Assess (Summ) 108(108): 1-7.

• Cumming, R. G. and Le Couteur, D. G. (2003). "Benzodiazepines and risk of hip fractures in older people: a review of the evidence." CNS Drugs 17(11): 825-837.

• de Jong et al. Drug-related falls in older patients: implicated drugs, consequences, and possible prevention strategies. Ther Adv Drug Saf. 2013. Aug;4(4):147-54.

• Donnelly, K., Bracchi, R., Hewitt, J., et al. (2017). "Benzodiazepines, Z-drugs and the risk of hip fracture: A systematic review and meta-analysis." PLoS One 12(4): e0174730.

• Ferracioli-Oda, E., Qawasmi, A. and Bloch, M. H. (2013). "Meta-analysis: melatonin for the treatment of primary sleep disorders." PLoS One 8(5): e63773.

• Glass, J., Lanctot, K. L., Herrmann, N., et al. (2005). "Sedative hypnotics in older people with insomnia: meta-analysis of risks and benefits." BMJ 331(7526): 1169.

• Halme, AS et al. Uncovering the source of new benzodiazepine prescriptions in community‐dwelling older adults’. Int J Geriatr Psychiatry 2013;28 (3):248-55

• Hansen, R. N., Boudreau, D. M., Ebel, B. E., et al. (2015). "Sedative Hypnotic Medication Use and the Risk of Motor Vehicle Crash." Am J Public Health 105(8): e64-69.

• Huedo-Medina, T. B., Kirsch, I., Middlemass, J., et al. (2012). "Effectiveness of non-benzodiazepine hypnotics in treatment of adult insomnia: meta-analysis of data submitted to the Food and Drug Administration." BMJ 345: e8343.

• Khong, T. P., de Vries, F., Goldenberg, J. S., et al. (2012). "Potential impact of benzodiazepine use on the rate of hip fractures in five large European countries and the United States." Calcif Tissue Int 91(1): 24-31.

• Kripke, D. F. (2016). "Mortality Risk of Hypnotics: Strengths and Limits of Evidence." Drug Saf 39(2): 93-107.

• Iaboni, A., Bronskill, S.E., Reynolds, K.B. et al. (2016). Changing Pattern of Sedative Use in Older Adults: A Population-Based Cohort Study. Drugs Aging 33, 523–533.

• Lyseng-Williamson, K. A. (2012). "Melatonin prolonged release: in the treatment of insomnia in patients aged >/=55 years." Drugs Aging 29(11): 911-923.

• Markota, M., Rummans, T. A., Bostwick, J. M., et al. (2016). "Benzodiazepine Use in Older Adults: Dangers, Management, and Alternative Therapies." Mayo Clin Proc 91(11): 1632-1639.

• Matheson E, Hainer BL. Insomnia: Pharmacologic Therapy. Am Fam Physician. 2017;96(1):29-35.

• Medicines N. Consumer information and education: Valerian. 2020.

• Miller, M., Sturmer, T., Azrael, D., et al. (2011). "Opioid analgesics and the risk of fractures in older adults with arthritis." J Am Geriatr Soc 59(3): 430-438.

• Mitchell, M. D., Gehrman, P., Perlis, M., et al. (2012). "Comparative effectiveness of cognitive behavioral therapy for insomnia: a systematic review." BMC Fam Pract 13(1): 40.

• Morgenthaler T, Kramer M, Alessi C, Friedman L, Boehlecke B, Brown T, et al. Practice parameters for the psychological and behavioral treatment of insomnia: an update. An american academy of sleep medicine report. Sleep. 2006;29(11):1415-9.

• Natural Medicines. Consumer Information and education: Melatonin. 2020.

• Park, S. M., Ryu, J., Lee, D. R., et al. (2016). "Zolpidem use and risk of fractures: a systematic review and meta-analysis." Osteoporos Int 27(10): 2935-2944.

• Pottie, K., Thompson, W., Davies, S., et al. (2018). "Deprescribing benzodiazepine receptor agonists: an evidence-based clinical guideline." Can Fam Phys In Press.

• Sateia MJ, Buysse DJ, Krystal AD, Neubauer DN, Heald JL. Clinical Practice Guideline for the Pharmacologic Treatment of Chronic Insomnia in Adults: An American Academy of Sleep Medicine Clinical Practice Guideline. J Clin Sleep Med. 2017;13(2):307-49.

• Saunders, K. W., Dunn, K. M., Merrill, J. O., et al. (2010). "Relationship of opioid use and dosage levels to fractures in older chronic pain patients." J Gen Intern Med 25(4): 310-315.

• Sirois, C., Ouellet, N. and Reeve, E. (2016). "Community-dwelling older people's attitudes towards deprescribing in Canada." Res Social Adm Pharm.

• Sivertsen, B., Omvik, S., Pallesen, S., et al. (2006). "Cognitive behavioral therapy vs zopiclone for treatment of chronic primary insomnia in older adults: a randomized controlled trial." JAMA 295(24): 2851-2858.

• Smith, M. T., Perlis, M. L., Park, A., et al. (2002). "Comparative meta-analysis of pharmacotherapy and behavior therapy for persistent insomnia." Am J Psychiatry 159(1): 5-11.

• Tannenbaum, C., Martin, P., Tamblyn, R., et al. (2014). "Reduction of inappropriate benzodiazepine prescriptions among older adults through direct patient education: the EMPOWER cluster randomized trial." JAMA Intern Med174(6): 890-898.

• Vicens, C., Bejarano, F., Sempere, E., et al. (2014). "Comparative efficacy of two interventions to discontinue long-term benzodiazepine use: cluster randomised controlled trial in primary care." Br J Psychiatry 204(6): 471-479.

• Wade, A. G., Crawford, G., Ford, I., et al. (2011). "Prolonged release melatonin in the treatment of primary insomnia: evaluation of the age cut-off for short- and long-term response." Curr Med Res Opin 27(1): 87-98.

• Weich, S., Pearce, H. L., Croft, P., et al. (2014). "Effect of anxiolytic and hypnotic drug prescriptions on mortality hazards: retrospective cohort study." BMJ 348: g1996.

• Xing, D., Ma, X. L., Ma, J. X., et al. (2014). "Association between use of benzodiazepines and risk of fractures: a meta-analysis." Osteoporos Int 25(1): 105-120.

• Zachariae, R., Lyby, M. S., Ritterband, L. M., et al. (2016). "Efficacy of internet-delivered cognitive-behavioral therapy for insomnia - A systematic review and meta-analysis of randomized controlled trials." Sleep Med Rev 30: 1-10.